Cullinan Therapeutics Inc
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
CGEM$11.23-4.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders' Equity
(in thousands, except share amounts)
| Preferred Stock · Common Stock · AdditionalPaid-In · AccumulatedOtherComprehensive · Accumulated · NoncontrollingInterests in · TotalStockholders’ | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | Capital | Loss | Deficit | Subsidiaries | Equity | |
| Balances at December 31, 2022 | — | $— | 45,796,449 | $5 | $585,320 | $(2,601) | $(47,695) | $— | $535,029 |
| Contributions from noncontrolling interests | — | — | — | — | — | — | — | 2,131 | 2,131 |
| Issuance of common stock | — | — | 3,310,000 | — | 38,388 | — | — | — | 38,388 |
| Issuance of preferred stock in exchange for common stock | 647,500 | — | (6,475,000) | (1) | 1 | — | — | — | — |
| Net issuance of common stock under equity-based compensation plans | — | — | 268,634 | — | 538 | — | — | — | 538 |
| Equity-based compensation | — | — | — | — | 30,438 | — | — | — | 30,438 |
| Unrealized gain on investments | — | — | — | — | — | 2,472 | — | — | 2,472 |
| Net loss | — | — | — | — | — | — | (153,162) | (1,939) | (155,101) |
| Balances at December 31, 2023 | 647,500 | — | 42,900,083 | 4 | 654,685 | (129) | (200,857) | 192 | 453,895 |
| Issuance of common stock and pre-funded warrants, net of issuance costs | — | — | 14,421,070 | 1 | 262,651 | — | — | — | 262,652 |
| Net issuance of common stock under equity-based compensation plans | — | — | 1,189,457 | 1 | 7,983 | — | — | — | 7,984 |
| Equity-based compensation | — | — | — | — | 37,824 | — | — | — | 37,824 |
| Acquisition of noncontrolling interests | — | — | — | — | (4,448) | — | — | — | (4,448) |
| Unrealized loss on investments | — | — | — | — | — | (4) | — | — | (4) |
| Net loss | — | — | — | — | — | — | (167,383) | (192) | (167,575) |
| Balances at December 31, 2024 | 647,500 | $— | 58,510,610 | $6 | $958,695 | $(133) | $(368,240) | $— | $590,328 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.